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Abstract
Background: Wilms tumor (WT) is one of the most common malignancies in childhood. With current therapy
protocols up to 90% of patients can be cured, but there is still a need to improve therapy for patients with
aggressive WT and to reduce treatment intensity where possible. Prior data suggested a deregulation of the
retinoic acid (RA) signaling pathway in high-risk WT, but its mode of action remained unclear.
Results: The association of retinoid signaling and clinical parameters could be validated in a large independent
tumor set, but its relevance in primary nephrectomy tumors from very young children may be different. Reduced
RA pathway activity and MYCN overexpression were found in high risk tumors as opposed to tumors with low/
intermediate risk, suggesting a beneficial impact of RA especially on advanced WT. To search for possible modes of
action of retinoids as novel therapeutic options, primary tumor cell cultures were treated in vitro with all-trans-RA
(ATRA), 9cis-RA, fenretinide and combinations of retinoids and a histone deacetylase (HDAC) inhibitor. Genes
deregulated in high risk tumors showed opposite changes upon treatment suggesting a positive effect of retinoids.
6/7 primary cultures tested reduced proliferation, irrespective of prior RA signaling levels. The only variant culture
was derived from mesoblastic nephroma, a distinct childhood kidney neoplasm. Retinoid/HDAC inhibitor
combinations provided no synergistic effect. ATRA and 9cis-RA induced morphological changes suggestive of
differentiation, while fenretinide induced apoptosis in several cultures tested. Microarray analysis of ATRA treated
WT cells revealed differential expression of many genes involved in extracellular matrix formation and osteogenic,
neuronal or muscle differentiation. The effects documented appear to be reversible upon drug withdrawal,
however.
Conclusions: Altered retinoic acid signaling has been validated especially in high risk Wilms tumors. In vitro testing
of primary tumor cultures provided clear evidence of a potential utility of retinoids in Wilms tumor treatment
based on the analysis of gene expression, proliferation, differentiation and apoptosis.
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Background
Wilms tumor (WT) - or nephroblastoma - is one of the
most frequent solid tumors in childhood. This malignant
kidney tumor affects about 1 of 10000 children. It arises
from undifferentiated renal precursors and often presents
with a triphasic histology consisting of blastemal, epithelial
and stromal elements. Mutations of CTNNB1, WT1 or
WTX were found in one third of WT, but in most cases
the genetic etiology is still unclear [1]. Standard therapy
according to the SIOP protocol consists of preoperative
chemotherapy followed by tumor resection, or primary
surgery for children under the age of six month. With cur-
rent therapy overall survival rate can exceed 90% [2,3], but
there is still a need for therapy improvement as prognosis
of patients with high risk and relapsing WT is still poor.
In a previous study using a microarray strategy to
detect new stratification markers for WT, the expression
levels of several genes involved in the retinoic acid (RA)
signaling pathway were found to be associated with dis-
ease progression [4]. These data suggested a contribution
of RA signaling to tumor progression and RA treatment
as an additional approach for therapy of WT. First hints * Correspondence: gessler@biozentrum.uni-wuerzburg.de
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mary WT cell cultures were treated with all-trans RA
(ATRA) [5].
The vitamin A derivative ATRA is capable of inducing
cell differentiation and inhibiting cell proliferation in var-
ious settings. It is already used in combination with che-
motherapy in acute promyelocytic leukemia (APL).
Retinoid therapy is also promising in pediatric malignan-
cies, e.g. high risk neuroblastoma therapy using 13cis-RA
[6]. While 13cis-RA is often administered in patients, it
presumably acts as a pro-drug while ATRA represents the
active form of RA [7]. Beside the classical retinoids ATRA,
13cis-o r9 cis-RA the synthetic retinoid fenretinide (4HPR)
is applied in cancer therapy. Whereas ATRA primarily
induces differentiation, fenretinide may act via apoptosis/
necrosis mechanisms [8].
Since WT originates from undifferentiated kidney pre-
cursor cells, ATRA-induced differentiation might be ben-
eficial to improve patient’s outcome. Furthermore, there
is evidence that inhibitors of histone deacetylases may
synergize with retinoic acid in inhibiting tumor growth,
e.g. in childhood neuroblastoma [9,10]. Until today next
to nothing is known about retinoids as therapeutic agents
in WT, since only one case of 13cis-RA treatment of
nephroblastomatosis, a WT precursor lesion, [11] and
administration of fenretinide in one patient with WT
[12] have been reported.
We have now validated prior microarray data in a much
larger and independent set of 200 WT samples by realtime
RT-PCR and we characterized the effects of RA treatment
in an in vitro system of primary WT cultures. We used
several different cell cultures established from fresh tumor
material and treated them with classical and synthetic reti-
noids or a combination of retinoids and a histone deacety-
lase (HDAC)-inhibitor to evaluate potential synergy.
Results
Expression of RA pathway genes in WT
Prior data from microarray experiments [4] had pointed
to deregulation of RA signaling pathway genes (RARB,
R A R G ,R A R R E S 1 ,R A R R E S 3 ,E N P P 2 ,C R A B P 2 ,C T G F ,
RAMP, MYCN, EZH2, PRAME and IGFBP3; Additional
file 1, Table S1) in Wilms tumors. Here we sought to
validate these findings in a much larger set of 200 WT
samples (167 samples after chemotherapy and 33 after
p r i m a r ys u r g e r y ) .T h ef o l l o wing clinical criteria were
evaluated: risk group (depending on histological subtype),
response to chemotherapy, and occurrence of metastasis,
relapse or death (Additional file 1, Table S2). The abso-
lute numbers of metastasis, relapse or death cases com-
parable in the high risk vs. low/intermediate risk groups,
but high risk tumors were of course less frequent (25 vs.
177). Comparison of WT after chemotherapy and pri-
mary resected specimens showed a higher expression of
RA-inducible genes in post-chemotherapy WT. This
could be in response to chemotherapy administration or
due to differences in tumor biology of the two groups.
We also detected a trend towards lower expression of
these genes in post-chemotherapy specimens from
younger vs. older patients. Omission of preoperative che-
motherapy is only recommended for children under
the age of 6 months, which have a much better prognosis
and may represent a poorly separable, variant entity [13].
Tumors with primary surgery in our set are characterized
by a much younger median age (4 vs. 35 months), but
numbers are too small to generate statistically reliable
data regarding the influence of age and/or therapy.
Therefore, only tumor specimens with preoperative
chemotherapy were included in subsequent statistical
analysis. The Mann-Whitney-U test was used in an
exploratory manner to compare expression levels of
genes according to the criteria listed without adjustment
of p-values to multiple testing. Detailed data on expres-
sion of all genes analyzed is summarized in Additional
file 1, Table S3. The most prominent differences in gene
expression were found when comparing low/intermediate
vs. high risk tumors (Figure 1): RARG, RARRES1,
RARRES3, CTGF, ENPP2 and IGFBP3 were downregu-
lated, while CRABP2, EZH2 and MYCN were overex-
pressed in high risk WT. Furthermore, higher expression
of MYCN was also seen in relapsing vs. non-relapsing
and in fatal cases. Tumors with a poor response to che-
motherapy, i.e. less than 50% reduction in volume during
preoperative chemotherapy, showed lower expression of
RARRES1 and RARRES3 compared to tumors with a
strong decrease in tumor volume. Thus, we detect similar
changes in RA pathway gene expression as described in
Zirn et al. [4], especially with respect to risk classification
and response to chemotherapy. Furthermore, we identify
differential expression with reduced RA pathway activity
in young age primary resected specimens.
RA treatment of primary WT cultures
To gain additional insight into the action of RA on
Wilms tumor cells and to test whether Wilms tumors
could benefit from retinoid treatment, we used primary
W Tc e l lc u l t u r e sa sa nin vitro system to study such
effects. Seven primary WT cultures derived from five
tumor samples (from 4 patients) were chosen for RA
treatment (Additional file 1, Table S4). Three of them
showed high baseline RA-signaling activity as measured
by expression of RARA/B/G and RARRES1/2/3 (ws539A,
ws539B and ws591) and they grew with a fibroblast-like
mesenchymal phenotype. Four cultures exhibited low
baseline RA-signaling activity (ws568li, ws568reA,
ws568reB and ws592) with all ws568-derived cultures
representing the mesenchymal phenotype, while ws592
was derived from a mesoblastic nephroma and consists
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been described in detail elsewhere [14]. Baseline expres-
sion of RA pathway genes was generally lower in cultured
cells compared to the original tumors, but the classifica-
tion into high vs. low expressing cases remained
unchanged.
To evaluate potentially divergent effects of clinically
employed RA derivatives we tested three retinoids and
one HDAC inhibitor. Each cell culture was treated with
10 μMA T R A ,9 cisRA or 4HPR and the combination of
10 μMA T R Ao r1 0μM 4HPR together with 150 nM
SAHA (HDAC inhibitor). These retinoid and SAHA
concentrations have been used before in in vitro studies
and can be reached in patients without severe side
effects [5,6,10].
Expression of RA pathway genes in treated WT cultures
Expression levels of genes differentially expressed in high
vs. low/intermediate risk WT were measured by quantita-
tive RT-PCR after 24 hours of treatment (this earlier time
point should reduce the effects of secondary changes). Six
of seven cultures showed concordant alterations in gene
expression upon RA treatment (Figure 2, Additional file 1,
Table S5): CRABP2, EZH2 and MYCN, which are over-
expressed in high risk WT, were down-regulated by RA
treatment in WT cultures. For CRABP2 changes were visi-
ble more clearly after 4 days of treatment. In all other
cases tested there was no big difference between one and
four days of treatment. RARB, RARRES1 and RARRES3 as
well as IGFBP3 were up-regulated during RA administra-
tion, while RARG remained largely unchanged. For CTGF
the direction of expression changes differed between the
WT cultures used: it was slightly up-regulated in ws539
and ws568, but slightly down-regulated in ws591. Overall,
the alterations in expression patterns of RA pathway genes
were opposite to the changes seen in high risk vs. low/
intermediate risk WT in six of seven cultures tested. Only
the primary culture ws592 did not show comparable
alterations of RA dependent genes and generally exhibited
less than 2fold up-/down-regulation with any treatment.
Figure 1 Relative expression of RA pathway genes in Wilms tumor subclasses. Box-plots represent 25% to 75% percentile and median of
gene expression relative to mean of the left-hand subgroup in each pair. P-values are given for Mann-Whitney-U test comparing tumor
subclasses for each gene tested. Risk group abbreviations: l/i, low/intermediate risk; hi, high risk
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changes between ATRA and 9cisRA treated cells. 4HPR
elicited a similar response, but RARRES1/3, IGFBP3 and
ENPP2 showed a reduced up-regulation. The HDAC inhi-
bitor SAHA had no additional effect on expression levels
beyond that seen with ATRA or 4HPR. Importantly,
expression changes did not depend on basal RA-signaling
activity, as alterations were rather similar in cell cultures
with either low or high basal expression of RARA/B/G
and RARRES1/2/3.
Cell proliferation under RA treatment
To analyze the impact of retinoids on proliferation of
WT cells, cell numbers were determined under retinoic
acid treatment for up to 14 days with all WT cultures
used before (Figure 3A). All retinoids (ATRA, 9cisRA,
4HPR) strongly reduced proliferation in most of the cul-
tures (ws539A, ws539B, ws568li, ws568reA, ws568reB
and ws591). Growth rate of ws592 was not influenced,
however, except for 4HPR, where a slight reduction was
seen. For both cultures derived from tumor ws539 4HPR
even exhibited a stronger effect than ATRA or 9cisRA,
while there was no obvious difference in the ws568 and
ws591 cultures. Again, the HDAC-inhibitor SAHA
showed no additional effect on proliferation when given
in combination with ATRA or 4HPR. Of note, indepen-
dent cultures derived from one patient reacted in the
same way (e.g. ws539A/ws539B and ws568li/ws568reA/
ws568reB; Additional file 2, Figure S1).
In all experiments retinoid concentrations of 10 μM
were used as these can be reached in patients as well. For
WT culture ws568li treatment with 0.1 μMa n d1μM
ATRA was tested in addition (Additional file 2, Figure
S2). Both ATRA concentrations reduced the proliferation
rate to the same extent as seen with 10 μM.
RA treatment induces morphological changes
Primary cultures that respond to retinoids by alterations of
gene expression and reduction of proliferation showed
morphological changes after 4 days of treatment. Both clas-
sical retinoids (ATRA and 9cisRA) induced enlargement of
cells with formation of strong actin fibers evident from
phalloidin staining (Figure 3B). Cell size measurements
(using an ellipsoid model) revealed an increase in cell size
of 2.6-/2.5-fold (ws539A), 2.9-/3.5-fold (ws568li) and 2-/
2.2-fold (ws591) with ATRA and 9cisRA, respectively (Fig-
ure 3C). 4HPR did not induce measurable changes, but in
some cultures large numbers of cells died (ws539, ws568,
see below). As before, ws592 cells neither exhibited mor-
phological changes nor cell death under retinoid treatment.
An increase in cell size and flattening of the cell body is
typical for senescent cells, but retinoid treated cells did
not show typical multinucleation. To test whether reti-
noids induced a state of senescence, SA-b-Gal-staining
was performed. Cultures treated for 4 days with ATRA or
9cisRA contained only few positive cells (less than 10%).
When 4HPR was used, no senescent cells could be found
(Additional file 2, Figure S3).
Apoptosis induction by 4HPR
4HPR did not induce the morphological alterations seen
for ATRA and 9cisRA, but many dead cells where found
Figure 2 Gene expression in RA treated WT cell cultures. Primary WT cells were treated with the drugs indicated for 24 h or 4 days (568li,
far right). Fold changes relative to untreated cells are depicted in the heat plot (log2 scaling). ATRA and 9cisRA caused similar changes of
expression levels while 4HPR showed slight differences for some genes. There was no obvious effect of additional SAHA application.
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ws591 fewer cells were affected (Figure 4). Analysis of
cleaved PARP as a late apoptosis marker revealed an
increase in apoptosis in ws539 and ws568 cultures after
4 days of 4HPR treatment. With ATRA and 9cisRA only
a slight induction of apoptosis could by detected in
those cultures. In contrast, there was no obvious induc-
tion of apoptosis in cultures ws591 and ws592. IHC
Figure 3 Retinoids affect proliferation and cell morphology. (A) Cell cultures ws539, ws568 and ws591 exhibit a decreased growth rate
when treated with ATRA, 9cisRA or 4HPR. Cultures shown represent examples since different individual cultures derived from the same tumor
sample/patient reacted in the same way. In culture ws592 no clear reduction of proliferation could be observed, except for 4HPR treatment. (B)
Morphological changes under RA treatment as observed in WT cell culture ws568li. ATRA and 9cisRA induced a pronounced increase of cell size
and formation of actin stress fibers. 4HPR rather led to cell shrinkage and detachment. Actin cytoskeleton is visualized in green (Phalloidin-FITC),
nuclei are stained with Hoechst 33342 (blue), scale bar: 50 μm. (C) Numerical representation of the cell size changes upon treatment in cell lines
ws539A, ws568li and ws591.
Wegert et al. Molecular Cancer 2011, 10:136
http://www.molecular-cancer.com/content/10/1/136
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80-100% apoptotic cells when treated with 4HPR or
4HPR+SAHA, while control ATRA or 9cisRA treated
cells were negative for cleaved Caspase3 (Additional file
2, Figure S4).
ATRA induces differentiation
To get insight into the response of primary WT cells to
RA treatment we compared staining patterns for mesench-
ymal and epithelial markers used before in the characteri-
zation of the respective cell cultures. There were no
striking or consistent changes after 4 days of treatment
indicating that these cells did not fully change their pheno-
type upon treatment (based on CAM5.2, CD105, and
CITED1; data not shown). To get a more global view of
alterations induced by retinoids we compared gene expres-
sion profiles of control and ATRA treated (4 days) ws568li
cells by microarray analysis (HG U133A Plus; Additional
file 1, Table S6). 552 Genes were found to be up-regulated
at least 2-fold (119 genes ≥ 4-fold) in ATRA-treated
compared to control cells and 417 genes were down-
regulated at least 2-fold (67 genes ≥ 4-fold).
To validate microarray data in other cell cultures quan-
titative RT-PCR was performed on control and ATRA-
treated (4 days) samples of ws489li, ws489re, ws539A,
ws568li, ws568reA and ws591 WT cultures. Genes from
different functional groups were analyzed (Figure 5;
Additional file 1, Table S7). All cultures tested showed
up-regulation of RA metabolism/pathway genes as found
in microarray analysis. For ws568li expression changes
from the microarray data could be validated for all genes
analyzed. Furthermore, all other cultures showed very
similar regulation of gene expression upon ATRA treat-
ment, albeit regulation is less prominent in cultures
ws539A and ws489li, or more pronounced in ws489re.
Gene ontology analysis of differentially expressed genes
(at least 2fold) identified several biological processes that
appear to be strongly affected (Additional file 1, Table S8).
Besides the expected changes affecting cell cycle and RA
metabolism/signaling genes (enrichment score (ES) 19.4
Figure 4 4HPR induced apoptosis in WT cell cultures. (A) 4HPR induced rounding and detachment of cells suggestive of cell death in cultures
derived from tumors ws539 and ws568, while only few or no detached cell were found after 4d of treatment in cultures ws591 and ws592. (B)
Increasing amounts of PARP cleavage as shown by Western blot analysis indicated apoptosis induction by 4HPR in WT cultures ws539 and ws568.
ATRA and 9cisRA are less effective. For ws591 and ws592 no increase in apoptosis could be detected. b-actin was used as a loading control.
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the extra cellular matrix (ECM, ES 8.5). The expression of
differentiation genes for bone/cartilage (ES 2.2), nervous
(ES 3.3) and neural crest/mesenchymal lineages (ES 2.8) as
well as for genes involved in angiogenesis (ES 6.2) was also
altered more frequently. Among the genes with higher
level alterations (> 4 ×) myogenic genes were enriched (ES
2.0). Nevertheless, these alterations in gene expression
Figure 5 Validation of microarray data by realtime RT-PCR. Changes in gene expression after 4 days of ATRA administration found by
microarray analysis in culture ws568li could be confirmed in different primary WT cells by realtime RT-PCR (heat map in log2 scaling).
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but rather to an induction of multiple differentiation path-
ways that may represent the plastic early embryonic state
of these tumor cells.
Long-term effects of retinoid treatment
To study the effect of long-term ATRA treatment
ws568li WT cells were kept in 10 μM ATRA containing
medium for 4 weeks. Subsequent omission of ATRA led
to an increase in proliferation within one week as com-
pared to continuous ATRA treatment (Figure 6A). When
ATRA was reapplied, growth rate was reduced again.
Although 4HPR exhibited a strong repressive effect on
cell proliferation and induced apoptosis, cells could still
be kept under 10 μM 4HPR for longer periods of time.
Similar to ATRA, removal of 4HPR reestablished prolif-
eration and proliferation again declined upon renewed
addition of 4HPR to the medium (Figure 6B). Both
experiments suggest that neither ATRA nor 4HPR exhi-
bit a persistent effect on WT cells and proliferation could
increase again if retinoids were discontinued, even after
long-term administration.
Discussion
Although cure rate of WT is high with standard therapy,
there is still a need for new therapeutic options, especially
Figure 6 Reversible effects of long-term retinoid treatment of WT culture ws568li. (A) WT cells were continuously cultivated in the
presence of 10 μM ATRA for 4 weeks. From time point t1 on cells were either kept in ATRA containing medium (ATRA) or cultivated in normal
medium (D10). At time point t2 ATRA was given again (D10®ATRA) to one of the cultures. (B) WT cells were continuously cultivated in 10 μM
4HPR for 2 month. At time point t1 two cultures were switched to normal medium (D10), leading to an increase in proliferation after 5 days. If
4HPR was given again from time point t2 on cell growth was reduced again.
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Additionally, a therapeutic strategy with fewer side effects
as compared to classical chemotherapy would be
desirable.
Our previous work provided first hints on deregulation
of RA signaling in advanced WT, which may represent a
starting point for new therapeutic approaches [4]. We
therefore analyzed the expression of RA pathway genes
in a larger, independent WT set to validate these find-
ings. Again, deregulation of RA pathway genes in high
risk vs. low/intermediate risk tumors was seen, albeit
findings on relapsing tumors could not be confirmed at
statistically significant levels. Others have described
altered expression of RA pathway genes when comparing
WT to fetal kidney [15]. In that study primary resected
WT samples had been investigated, indicating that dereg-
ulation of RA signaling may be a general event in WT,
independent of therapeutic strategy. Another study by
Gupta and colleagues [16] revealed increased expression
of CRABP2 in late stage Wilms tumors. There was evi-
dence that this may be driven by elevated MYCN expres-
sion. In our samples we likewise found significantly
elevated levels of MYCN in high risk, and relapsing
tumors, but it remains to be tested if there is a direct
relationship between MYCN levels and RA signaling
activity e.g. in the different risk groups..
The comparatively smaller number of tumors in our
study with primary surgery showed a lower expression of
most RA pathway genes as compared to the larger cohort
of post-chemotherapy samples. However, they are also
characterized by a much earlier age at diagnosis (median
age of 4 vs. 35 months). Most belong to a group of low
risk tumors (age < 6 months, < 500 g, stage I, no preopera-
tive chemotherapy) that are known to be curable by sur-
gery alone as shown in NWTSG/COG [13]. Taking the
data by Li et al. [15] into account, it thus appears that the
differences in both, age and clinical subtype of our WT
with primary surgery could be an important contributor to
the divergent gene expression patterns observed between
these two cohorts and levels of RA pathway activation
may become more relevant only at slightly later ages. On
the other hand, it is plausible that chemotherapy and con-
comitant local damage/inflammation may lead to an
induction of RA signaling as part of a defense mechanism
as seen in experimental glomerulonephritis [17]. Of note,
exogenous RA had additional beneficial effects despite
induction of the endogenous RA system in this case.
Since the available data point to the RA signaling path-
way as an interesting target for WT therapy, we tested
different retinoids in an in vitro model using primary
WT cell cultures. Retinoid administration was able to
inverse expression of genes found to be deregulated in
h i g hr i s kW Tt oam o r ef a v o r a b le pattern characteristic
for low/intermediate risk WT. Surprisingly, this effect
was seen irrespective of the initial levels of expression of
the corresponding genes in these cultures. Together with
the strong growth suppression observed in vitro for all
retinoids tested this clearly hints at a possible therapeutic
utility of such a treatment. This is supported by the
impressive clinical success of retinoid treatment in one
case report of nephroblastomatosis, a WT precursor
lesion, where a significant decline of kidney volumes was
observed over a period of 1 year [11]. The comparatively
poor response seen for ws592, a culture derived from
mesoblastic nephroma, an early childhood tumor sepa-
rate from WT, suggests that the effects observed with
our cultures of classical WT may be rather specific and
not due to general or unspecific effects of retinoids on
cultured human cells and it may further set this tumor
apart from classical WT.
Alteration of cell morphology under ATRA treatment
points to an ATRA induced differentiation of WT cells,
which is well known from other cell lines. WT specimens
often contain different cell types like adipocytes, muscle
cells, cartilage or bone structures or neuronal elements
highlighting the differentiation potential of WT cells. We
thus analyzed global gene expression changes in one of
the treated WT cultures and we were able to validate
these for selected genes in other cultures. Nevertheless,
these patterns did not define a singular differentiation sta-
tus or direction of ATRA treated WT cells, since a variety
of genes involved in diverse differentiation processes were
affected. This suggests that RA treatment may not induce
terminal differentiation in treated WT cells, but partially
supports multiple lineages.
The incomplete RA-induced differentiation is in line
with results from long-term treatment, where neither
ATRA nor 4HPR exhibited a persistent effect on WT cell
morphology and where proliferation was again resumed if
retinoids were discontinued. Thus, under in vitro condi-
tions retinoids are not able to induce terminal differentia-
tion, but they decrease cell proliferation. This would
severely limit the usefulness of retinoid treatment since
long-term treatment would lead to more significant side
effects in young children. Similar results have been
reported for rhabdomyosarcoma cells, where ATRA led to
growth suppression and morphological changes, but these
cells did not complete differentiation into multinucleated
myotubes [18]. For neuroblastoma cell lines short-term
ATRA treatment was sufficient to permanently reduce
growth rate in some cases, but again there were cultures
that increased proliferation upon ATRA removal [19]. An
important caveat is that ATRA may act in a slightly differ-
ent way in the in vivo situation, where tumor cells may
encounter different endogenous stimuli as well as interac-
tions with the ECM, immune cells or other neighboring
cells that may ultimately fix differentiation and thereby
contribute to tumor control.
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lead to morphological changes indicative of differentia-
tion, but rather induced apoptosis in most of the WT
cells tested. Similar findings have been reported earlier
for neuroblastoma cells: while ATRA drove differentia-
tion and thus reduced overall cell proliferation, 4HPR
induced growth arrest via induction of programmed cell
death, without signs of differentiation [20]. As 4HPR
can act independent of the typical RA signaling pathway
through activation of ROS, lipid second messengers or
mitochondrial pathways [21], it may represent an alter-
native approach, useful in ATRA resistant cases. Never-
theless, the similarity in gene expression patterns
induced in treated cultures suggests that some overlap
in signaling modes likely exists.
A further option for retinoid treatment could be the
combination therapy with HDAC-inhibitors, as HDACs
are part of the co-repressor complexes that inhibit
expression of RA-target genes. Synergistic effects have
already been described for APL cell lines where HDAC-
inhibitors potentiate RA-induced differentiation and even
restored RA-response in RA resistant cell lines [22]. The
HDAC-inhibitor SAHA we used has been investigated
before in neuroblastoma cell lines and an in vivo xeno-
graft model [10], where combination therapy had a syner-
gistic effect on differentiation and apoptosis and it
improved host survival. However, in all our WT cell cul-
tures SAHA exhibited no synergistic effect, neither in
combination with ATRA nor 4HPR, suggesting that WTs
may behave differently.
In summary, we provide novel insight into the response
of WT cells to retinoic acid based treatment that suggests
that retinoid administration may be an additional or alter-
native approach for therapy of Wilms tumors, esp. in
those resistant to conventional therapy. Important caveats
remain, however: in vivo models (e.g. xenografts in nude
mice) are needed that better reflect the physiological situa-
tion in patients. Especially the reversibility of RA induced
alterations in vitro must be critically assessed in the in vivo
situation. Furthermore, the interplay of classical che-
motherapy regimens based on cell damage with agents
that promote differentiation and tumoristasis may prove
difficult and again calls for improved modelling.
Conclusions
We had initially identified altered retinoic acid signaling
in different subgroups of Wilms tumors. These finding
have now been extended and corroborated in a large set
of 200 additional samples. Furthermore, we found evi-
dence for age and stage/therapy-dependent expression of
RA-pathway genes. We went on to evaluate the effects
different retinoids on cultured primary Wilms tumor
cells. We detected a strong decrease in proliferation that
appears to be coupled to partial differentiation, especially
in the case of classical retinoids. On the other hand, the
synthetic derivative fenretinide seems to act primarily via
induction of apoptosis. Nevertheless, all agents induced
gene expression changes suggestive of partial differentia-
tion in several directions. The cells remained in a rather
plastic state as the antiproliferative effects of all retinoids
were dependent on continuous presence of these agents.
This is in line with results from other tumor entities and
suggests that retinoids may supplement current thera-
peutic strategies, which is also evident from singular case
reports in the literature.
Materials and methods
WT Samples and Clinical Data
Frozen tumor tissue and corresponding control samples
(blood or normal kidney) were obtained from hospitals
participating in the SIOP93-01/GPOH and SIOP2001/
GPOH WT studies. Clinical data and reference pathol-
ogy are from the central GPOH study registry. Patients
categorized as relapse free had at least two years of fol-
low-up, good response to chemotherapy was taken as a
decrease in tumor volume of more than 50%.
Isolation of DNA and RNA
Total RNA and DNA from tumor tissue and cell cultures
were isolated using QIAGEN or Macherey-Nagel kits.
Genomic DNA from kidney and blood samples were puri-
fied as described before [23].
Realtime RT-PCR
2.5 μg of total RNA were used per cDNA synthesis reac-
tion using the RevertAid First Strand cDNA synthesis kit
(MBI Fermentas, St.Leon-Rot, Germany) with oligo dT
primers. After cDNA synthesis water was added to a final
volume of 200 μl. Realtime-PCR was conducted as
described before with SybrGreen quantification [24]. Pri-
mers and PCR conditions used are listed in Additional file
1, Table S9. The housekeeping gene HPRT was used to
normalize expression levels. All measurements were per-
formed at least twice and mean values were calculated.
Statistical analysis
Statistical analyses were performed with SPSS (Version
16.0). Mann-Whitney-U tests were used for comparison of
expression level of genes analysed in the respective classes
of metastasis, relapse, mortality, response to chemotherapy
or histological subtype. The influence of RA treatment on
WT cell size was tested in the same way.
Cell culture and RA treatment
Primary WT cell cultures were maintained in Dulbecco’s
Modified Eagle Medium supplemented with 10% fetal
calf serum and 1% penicillin/streptomycin (D10). Estab-
lishing and characterization of primary WT cell cultures
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with either 10 μM all-trans retinoic acid (ATRA, Sigma
Aldrich), 10 μM9 - cis retinoic acid (9cisRA, Sigma
Aldrich), 10 μM fenretinide (4-hydroxy(phenyl)retina-
mide, 4HPR, Sigma Aldrich), 10 μM ATRA + 0.15 μMo f
the HDAC-inhibitor suberoylanilide hydroxamic acid
(N
1-hydroxy-N
8-phenyl-octanediamide, SAHA, Cayman
Chemicals) or 10 μM4 H P R+0 . 1 5μM SAHA. Retinoid-
containing medium was refreshed every second day.
Untreated control cells received D10 with 1 μl/ml
dimethyl sulfoxide that was used as solvent for retinoids.
Determination of cell numbers
5×1 0
4 cells per well were seeded in 12well cell culture
plates and allowed to adhere overnight. The following day
(0 d) RA treatment was started. For each time point at
least two samples were counted using a Neubauer cham-
ber and mean values were calculated.
Phalloidin staining
Cells were seeded on cover slips, incubated overnight and
treated with retinoids as indicated for 4 days. Fixation was
done with 2% paraformaldehyde in PBS (phosphate buf-
fered saline) for 20 min at room temperature followed by
washing and 10 min permeabilisation with PBS-T (PBS,
0.2% Tween). Actin filaments of cells were stained with 15
μg/ml of FITC conjugated Phalloidin (Sigma Aldrich) for
45 min and nuclei were counterstained with Hoechst
33342 (Invitrogen, 1:10, 000). Cover slips were mounted
with Mowiol and cells were examined with an inverted
microscope (Leica DMI 6000B). For cell size determina-
tion length and width of cells were measured using the
microscope software (Leica Application Suite 1.7.0) and
cell area was approximated using an ellipsoid model (A =
1/2*π*width*length).
Senescence associated b-Gal-staining
Cells grown in 6-well cell dishes were washed with PBS
(pH 7.2), fixed for 10 min with 0.5% glutaraldehyde and
again washed with PBS (pH 7.2) + 1 mM MgCl2. Staining
solution (1.2 ml) contained 1 mg/ml X-Gal (5-bromo-4-
chloro-3-indolyl-beta-D-galacto-pyranoside), 0.12 mM
K3Fe(CN)6,0 . 1 2m MK 4Fe(CN)6 and 1 mM MgCl2 in PBS
(pH 6.0). After 3 to 10 h of incubation at 37°C staining
was stopped by washing with PBS + 1 mM MgCl2 (pH
7.2).
Western blot analysis
5×1 0
6 cells were lysed in 50 μl RIPA buffer (150 mM
NaCl, 100 mM Tris-HCl pH 7.4, 2% Nonidet P40, 1%
sodium deoxycholate, 0.2% sodium dodecyl sulphate, 50
μg/μl phenylmethylsulfonyl fluoride and complete pro-
tease inhibitor cocktail (Roche)) for 45 min on ice, centri-
fuged for 30 min at 4°C and protein concentration of
lysates was determined by Bradford assay (Biometra).
Equal amounts of proteins were separated on 10% SDS-
PAGE (sodium dodecyl sulfate polyacrylamide gel) and
transferred to nitrocellulose membrane (PROTRAN,
Schleicher&Schuell). Antibodies used for western blot ana-
lysis were cleaved PARP (1:1, 000; clone F21-852, BD
Pharmingen), b-Actin (1:10, 000; clone C4, Santa Cruz
Biotechnology) and mouse-IgG (1:5, 000; horseradish per-
oxidase conjugated, polyclonal AP124P, Chemicon).
Detection was carried out using ECL chemiluminescent
detection.
Immunohistochemical analysis
Formalin fixed primary cells were used for immunohis-
tochemical analysis. Preparation of cells blocks and
staining procedure were described in detail in Wegert
et al. [14]. Antibodies used were cleaved Caspase3 (rab-
bit monoclonal 5A1E, 1:100, Cell Signaling), CAM5.2
(1:5, BD Biosciences), CD105 (clone MEM-226, 1:200,
Immunotools) and CITED1 (rabbit polyclonal, 1:100,
Neo Markers)
Microarray analysis
Total RNA of control and ATRA treated WT cells was
used for microarray analysis on Human Genome U133
Plus 2.0 Gene Arrays (Affymetrix, Santa Clara, CA). Label-
ing and washing were performed according to the stan-
dard Affymetrix protocol. The arrays were scanned using
a GeneChip
® Scanner 3000 (Affymetrix). Data analysis
and quality control was done using different R packages
from the Bioconductor project http://www.bioconductor.
org. Probe sets were summarized using the RMA algo-
rithm and resulting signal intensities were normalized by
variance stabilization normalization (vsn) [25]. Functional
clustering of differentially expressed genes was done with
DAVID (Database for Annotation, Visualization and Inte-
grated Discovery, [26]).
Additional material
Additional file 1: Table S1: RA pathway genes included in expression
analysis.. Table S2: Statistics of expression of RA genes, all WT samples.
Table S3: Statistics of expression of RA genes, WT with chemotherapy
only. Table S4: Characteristics of primary WT cultures used. Table S5:
Gene expression in RA treated WT cells (fold change compared to
untreated cells). Table S6: Top 50 regulated genes of ATRA treated
ws568li cells (microarray analysis). Table S7: Validation of microarray data
by realtime RT-PCR (fold change). Table S8: Functional cluster analysis of
ATRA regulated genes in WT cells. Table S9: Real-time RT-PCR primers
and conditions.
Additional file 2: Figure S1. All cell cultures derived from tumors of
one patient reacted in the same way to RA treatment. Ws568reA and
ws568reB showed reduction of growth rate under RA treatment like
ws568li did. Figure S2. Low ATRA concentrations are sufficient to reduce
cell growth. ws568li cells were treated with different ATRA
concentrations, which all reduced cell proliferation to the same extent.
Figure S3. SA-b-Gal staining of RA-treated ws568li cells. ATRA and 9cisRA
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treated cells showed no senescence. Figure S4. Caspase3 IHC staining of
ws539A cells after 4d of RA treatment. Fenretinide and the combination
of 4HPR and the HDAC inhibitor SAHA induced apoptosis in primary WT
cells while ATRA, 9cisRA and ATRA combined with HDAC inhibitor did
not.
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